从高危状态向临床及重症系统性红斑狼疮进展涉及生物制剂可能逆转的分子失调
该多中心前瞻性研究对具有提示SLE非诊断性特征个体的基线血RNA测序分析发现,进展者干扰素-α/γ及炎症细胞因子活性增强,17基因易感特征可预测转化(外部验证AUC 0.80,95%CI 0.65-0.94),且通路异常在计算机模拟中可被阿尼鲁单抗和贝利尤单抗逆转。
要点
- 高危个体存在代谢、细胞因子信号、血液及应激反应通路失调。
- 进展者干扰素-α/γ及炎症细胞因子活性增强并随SLE分类而加剧。
- 17基因特征预测转化AUC 0.80(95%CI 0.65-0.94), IFN信号和氧化磷酸化放大提示严重度。
核心结论
- 干扰素-α/γ和炎症细胞因子特征标志 evolving/early SLE,而干扰素信号和氧化磷酸化放大提示疾病严重度。
研究设计与样本
- 多中心前瞻性研究,纳入具有提示SLE非诊断性特征的个体,基线血RNA测序比较进展为可分类SLE者(n=36)与未进展者(n=36),并与健康对照(n=42)和早期SLE(n=43)比较。
- 使用独立高危队列(进展者n=15,未进展者n=20)验证分子分类器。
主要发现
- 高危个体表现出代谢、细胞因子信号、血液学和应激反应通路失调。
- 进展者 vs 未进展者显示干扰素-α/γ和炎症细胞因子活性增强,并经基因集富集分析和共表达分析证实,且在SLE分类时加剧。
- 基因模块特征值模式的无监督建模揭示进展者间分子异质性,差异涉及p53/胰岛素活性和Toll样受体信号。
- 表征了一个17基因易感特征,在外部队列中预测转化的受试者操作特征曲线下面积为0.80(95%CI: 0.65-0.94)。
- 从健康和高危状态到早期SLE和狼疮肾炎的连续分析显示干扰素-α/γ、血红素代谢和氧化磷酸化通路逐步上调,已建立疾病中额外干扰素相关基因激活。
关键数值与推荐
- 17基因易感特征预测转化AUC 0.80(95%CI: 0.65-0.94)。
- SLE易感性和进展特征在计算机模拟中显示可被阿尼鲁单抗和贝利尤单抗逆转。
临床怎么用
- 血液分子谱分析可能有助于风险分层并合理化早期生物制剂方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Understanding the molecular events underlying systemic lupus erythematosus (SLE) onset and progression can facilitate early intervention strategies. We explored transcriptomic changes during progression from preclinical to clinical and advanced SLE, and assessed their potential reversibility by targeted agents. METHODS: This includes multicentre prospective study of individuals with nondiagnostic features suggestive of SLE. Baseline blood RNA-sequencing was performed in groups who progressed to classifiable SLE or not (n = 36 each), and compared with healthy (n = 42) and early SLE (n = 43). Transcriptome analysis included supervised methods, gene module-based clustering, and drug reversibility/repurposing pipelines with publicly available data. An independent at-risk cohort (n = 15 progressors, n = 20 nonprogressors) was used to validate molecular classifiers. RESULTS: At-risk individuals exhibited deregulated metabolic, cytokine signalling, haematologic, and stress-response pathways. Progressors vs nonprogressors showed heightened interferon (IFN)-alpha (α)/gamma (γ) and inflammatory cytokine activity, corroborated by Gene Set Enrichment Analysis and coexpression analysis, and intensified during SLE classification. Unsupervised modelling of gene module-eigengene patterns revealed molecular heterogeneity among progressors, differing in p53/insulin activity and Toll-like receptor (TLR) signalling. Importantly, we characterised a 17-gene susceptibility signature that predicted transition with an area under the curve 0.80 of the receiver operating characteris (95% CI: 0.65-0.94) in the external cohort. Analysis across the continuum-from healthy and at-risk states to early SLE and lupus nephritis-revealed stepwise upregulation of IFN-α/γ, haem metabolism, and oxidative phosphorylation pathways, with additional IFN-related genes activated in established disease. SLE susceptibility and progression signatures demonstrated in silico reversibility by anifrolumab and belimumab. CONCLUSIONS: IFN-α/γ and inflammatory cytokine signatures characterise evolving/early SLE, whereas amplification of IFN signalling and oxidative phosphorylation denotes severity. Blood molecular profiling may aid risk stratification and rationalise early biologic approaches.
引用
- Papanikolaou S, Emmanouilidou E, Adamichou C, et al. Progression from at-risk state to clinical and severe systemic lupus erythematosus involves molecular dysregulations potentially reversible by biologics: implications for early diagnosis and treatment. Ann Rheum Dis. 2026. PMID: 41792021. doi:10.1016/j.ard.2026.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。